Note: All changes are versus the prior-year period unless otherwise stated
"Even with some headwinds from the COVID-19 pandemic, we achieved business [earnings per share] growth supported by continued outstanding sales from Dupixent, a focus on efficiency and smart spending," remarked CEO Paul Hudson.
Sanofi said that profit in the quarter was boosted by a €7.2-billion ($8.5 billion) gain on a share repurchase transaction completed in May with Regeneron Pharmaceuticals.
Sanofi now expects business earnings per share this year to grow between 6% and 7% at constant exchange rates, lifted from an earlier estimate of 5%. The company said that new patient starts and elective procedures are forecast to recover in the third quarter, but will "not yet…return to pre-COVID-19 levels." Sanofi added that vaccinations are also expected to recover, although these are not likely to reach pre-pandemic levels either, while travel vaccines will continue to be impacted.
To read more Top Story articles, click here.